Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
نویسندگان
چکیده
منابع مشابه
Outcomes after 90Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard therapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are chemosensitive. The combination of carmustine, etoposide, cytarabine, and melphalan (BEAM) is commonly used as a conditioning regimen. The addition of yttrium-90 ((90) Y)-ibritumomab tiuxetan (Zevalin(®)) to BEAM ...
متن کاملNonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.
In 2008, we reported favorable 5-year outcomes of nonmyeloablative allogeneic stem cell transplantation after fludarabine, cyclophosphamide, rituximab (FCR) conditioning for relapsed and chemosensitive follicular lymphoma. However, innovative strategies were still needed to treat patients with chemorefractory disease. We therefore subsequently performed a trial in which (90)Y-ibritumomab tiuxet...
متن کاملA Case Report of a Metastatic Primary Gastric Lymphoma; Diffuse Large B-Cell or Burkitt Lymphoma?
Introduction: Primary gastric lymphoma (PGL) is a rare tumor, whose differential diagnosis may become complicated without precise immunohistochemistry (IHC) and genetic analysis. Case Presentation: A 33-year-old woman presented with gastric cancer and had undergone gastrectomy without precise IHC and staging in another center. Inappropriate IHC after surgery showed diffuse large B-cell lymphom...
متن کاملA Case Report of a Metastatic Primary Gastric Lymphoma; Diffuse Large B-Cell or Burkitt Lymphoma?
Introduction: Primary gastric lymphoma (PGL) is a rare tumor, whose differential diagnosis may become complicated without precise immunohistochemistry (IHC) and genetic analysis. Case Presentation: A 33-year-old woman presented with gastric cancer and had undergone gastrectomy without precise IHC and staging in another center. Inappropriate IHC after surgery showed diffuse large B-cell lymphom...
متن کاملPhase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
The majority of diffuse large B-cell lymphoma (DLBCL) tumors contain mutations in histone-modifying enzymes (HMEs), indicating a potential therapeutic benefit of histone deacetylase inhibitors (HDIs), and preclinical data suggest that HDIs augment the effect of rituximab. In this randomized phase 2 study, we evaluated the response rate and toxicity of panobinostat, a pan-HDI administered 30 mg ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2018
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-17-3561